Guangzhou Baiyunshan Pharmaceutical (GZPHF)

Wednesday

10:54 PM

ThesisThe recent regulatory approval and strategic partnerships are expected to enhance growth prospects, leading to a more favorable outlook for the stock.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$75.4B	$85.3B	$89.6B
Rev. Growth	+0.6%	+13.1%	+5.1%
EPS	$1.82	$2.02	$2.13
EPS Growth	+4.6%	+10.8%	+5.7%
P/E (fwd)	1.3×	1.2×	1.1×

★ Analysts see FY2026 revenue reaching $85.3B — +13.1% growth in a single year.

The Bull Case for Growth

01Recent regulatory approval for a new oncology drug could expand market share by 15% in the next year.
02Partnership with a leading European biotech firm to co-develop a new drug, potentially increasing R&D efficiency by 20%.
03Declining raw material costs could improve gross margins by 2% over the next fiscal year.
04Increased demand for traditional Chinese medicine
05Growth in personalized medicine and targeted therapies
06Regulatory approvals for new drugs
07Market share changes in the Chinese pharmaceutical sector
08Pricing strategies and reimbursement policies

FY2025 Snapshot

Revenue: $75.4B
Rev. Growth: +0.6%
Gross Margin: 15.2%
Op. Margin: 4.0%
Net Margin: 3.9%
Net Income: $2.9B
NI Growth: +2.5%
EPS: $1.82
1Y Return: -0.4%

My Notes

"Management emphasized, 'Our commitment to innovation and strategic collaborations positions us well for future growth.'"
Moat: GZPHF's established brand and extensive distribution network provide a significant competitive advantage in the Chinese market.
value - The low price-to-sales and price-to-book ratios suggest potential undervaluation.
Interest rates affect GZPHF primarily through the cost of financing for R&D and capital expenditures…
Watch on earnings: Prescription drug sales growth, R&D expenditure as a percentage of revenue, Market share in key therapeutic areas.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $85.3B to $89.6B as recent regulatory approval for a new oncology drug could expand market share by 15% in the next year.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.